10-Q: BioLargo Q2 2025 Revenue Drops 38%, Net Loss Widens

BioLargo, Inc. reported a significant 38% decline in total revenue and a widened net loss for the six months ended June 30, 2025, raising substantial doubt about its ability to continue as a going concern.

Summary

• Total revenue for the six months ended June 30, 2025, decreased by 38% to $6.046 million, down from $9.773 million in the same period of 2024.
• Product revenue declined by 49% to $4.809 million, primarily due to a decrease in sales volume of the Pooph-branded pet odor control product.
• Service revenue increased by 300% to $1.237 million for the six months ended June 30, 2025, compared to $309,000 in 2024.
• The net loss for the six months ended June 30, 2025, widened to $3.803 million, compared to a net loss of $1.555 million in the prior year period.
• Cash used in operating activities was $3.948 million for the six months ended June 30, 2025, a significant increase from cash provided by operating activities of $330,000 in the same period of 2024.
• The company received $3.699 million from financing activities during the six months ended June 30, 2025, up from $2.082 million in 2024.
• As of June 30, 2025, cash and cash equivalents stood at $3.471 million, a slight decrease from $3.548 million at December 31, 2024.
• A $3.764 million accounts receivable from ONM Environmental's largest customer (Customer A, Pooph Inc.) was converted into a note receivable on June 6, 2025, with payments due through July 3, 2026, at 10% interest.
• Clyra Medical Technologies, a 50% owned subsidiary, significantly increased its debt obligations, issuing $436,000 in secured promissory notes, $250,000 in convertible promissory notes, and $575,000 in guaranteed notes during the six months ended June 30, 2025.

Sentiment

Score: 3

Explanation: The company faces severe financial challenges, including a substantial decline in revenue, widening net losses, and significant cash burn from operations, leading to a 'going concern' warning. While there are promising technology developments and some financing activities, the current financial performance and operational risks outweigh these positives, indicating a highly precarious situation.

Positives

• Service revenue increased by 300% for the six months ended June 30, 2025, reaching $1.237 million.
• BLEST (engineering segment) secured new contracts to provide air quality control compliance services to additional U.S. Air Force bases, increasing ongoing contract-based revenue to approximately $100,000 per month.
• The Aqueous Electrostatic Concentrator (AEC) for the PFAS project in New Jersey has been built and is ready for delivery and installation, awaiting completion of other facilities.
• The company is exploring a collaboration with the US EPA for rigorous third-party pilot study validation of the AEC technology, which could significantly facilitate market adoption.
• The Cellinity battery technology is undergoing prototype manufacturing and testing, with preliminary internal tests confirming exceptional performance claims like stability, reliability, quick charge/discharge, and safety (no fire/explosion).
• The company has secured channel partner agreements with several sales representative organizations for the AEC, ensuring coverage for most of the continental United States.
• Clyra Medical Technologies has formalized relationships with multiple wholesale distributors and sales agents and has infrastructure in place for product sales.

Negatives

• Total revenue decreased by 38% for the six months ended June 30, 2025, compared to the same period in 2024, primarily due to a 49% decrease in product sales.
• Net loss widened significantly to $3.803 million for the six months ended June 30, 2025, from $1.555 million in the prior year.
• Cash used in operating activities increased substantially to $3.948 million for the six months ended June 30, 2025, compared to cash provided of $330,000 in the prior year.
• The company explicitly states "substantial doubt about our ability to continue as a going concern" due to insufficient gross profits to fund current operations.
• ONM Environmental's revenue decreased by 44% for the six months ended June 30, 2025, primarily due to a decline in sales volume of the Pooph-branded pet odor product, over which the company has no control regarding marketing and sales activity.
• Clyra Medical Technologies, a partially owned subsidiary, has not yet begun commercial sales of its products and incurred total costs and expenses of $2.580 million for the six months ended June 30, 2025, an increase from $1.154 million in 2024.
• BioLargo Energy Technologies, Inc. (BETI) has not generated revenue and incurred $217,000 in costs and expenses for the six months ended June 30, 2025.
• The company has a material weakness in internal controls related to financial statement closing due to limited financial and personnel resources, distributed operations, and lack of sophisticated reporting systems.

Risks

• Substantial doubt about the ability to continue as a going concern due to insufficient gross profits to fund current operations and reliance on future investment capital or asset conversion.
• High customer concentration risk, with one customer (Pooph Inc.) accounting for 69% of consolidated revenue for the six months ended June 30, 2025.
• Inability to control the marketing and sales activity of the Pooph brand, which significantly impacts ONM Environmental's revenue.
• Lengthy and arduous sales cycles in the water and wastewater industry, potentially taking months or multiple years for large projects.
• Need for additional investment capital to fund business plans and investments in new technologies.
• Risk of not being able to raise additional cash through gross profits or financing activities, potentially leading to curtailment of operations.
• Uncertainty regarding the award of pending or future government grants for research and development activities.
• Material weakness in internal controls over financial reporting due to limited financial and personnel resources, distributed operations, and lack of sophisticated reporting systems.
• Challenges in managing quality and timely performance, as well as access to qualified staff, for BLEST's growing list of customers and internal projects.
• Reliance on contract manufacturers to meet customer demands in the near term as infrastructure and workforce capabilities scale up.
• Clyra Medical's reliance on future commercial sales to generate revenue and its increasing costs and expenses without corresponding revenue.
• BETI's reliance on recruiting business partners to facilitate capital investment and its inability to predict when it will generate revenue.
• Exposure to credit loss for cash balances exceeding the FDIC insurance limit of $250,000.
• Potential for actual results to differ materially from forward-looking statements due to various factors, including those outlined in the annual report on Form 10-K.

Future Outlook

The company does not believe gross profits for the year ending December 31, 2025, will be sufficient to fund current operations and expects to continue needing further investment capital for business plans and new technologies. Management may choose to curtail portions of operations if unable to raise additional cash through gross profits or financing activities. The company is focused on recruiting business partners to facilitate capital investment for its Cellinity battery and is unable to predict when BETI will generate revenue. Clyra Medical has not yet begun commercial sales and management is not yet in a position to disclose when it believes Clyra Medical will begin generating revenue.

Management Comments

• We do not believe gross profits in the year ending December 31, 2025, will be sufficient to fund our current level of operations for the reminder of the year, and therefore expect we will continue to be limited in terms of our capital resources, and therefore expect to continue to need further investment capital to fund our business plans and investments in our new technologies.
• If we are unable to raise additional cash through gross profits or financing activities, management may choose to curtail portions of our operations.
• Because the Pooph brand is owned and marketed by a third party, ONM Environmental has no control over its marketing and sales activity.
• Because the brand has only been on the market for three years, it is difficult to identify trends and uncertainties in sales volumes, especially so for longer periods of time. We expect annual revenues for the year ending December 30, 2025, to decrease as compared with 2024.
• Securing sales in the water and wastewater industry is a very technically intensive process and can be long and arduous. The entirety of the sales cycle can be lengthy, in some cases even taking many months or, in the case of very large projects, multiple years.
• We are working carefully to find balance to help ensure we meet the demands of both in a practical customer centric and capital conserving way. It may be for example, when we secure larger and larger contracts for PFAS or Garrett Callan related work, we will need to depend heavily on our contact manufactures to meet the customer demands in the near term as we scale up our infrastructure and work force capabilities.
• Management is not yet in a position to disclose when it believes Clyra Medical will begin generating revenue.
• We are focused on recruiting business partners to facilitate capital investment, and are unable to predict when BETI will generate revenue.
• Our management, including our chief executive officer and chief financial officer, does not expect that our disclosure controls or our internal control over financial reporting, or any system we design or implement in the future, will prevent or detect all errors and all fraud.

Industry Context

The company operates in the cleantech sector, addressing critical environmental challenges such as PFAS contamination and water treatment, and is also developing solutions in battery energy storage and medical devices. The decline in revenue from its key pet odor control product (Pooph) highlights the volatility of relying on third-party branded consumer products. The long sales cycles in the water and wastewater industry, as noted by management, are typical for complex infrastructure projects, requiring significant upfront investment in engineering and pilot studies before commercial scale-up. The pursuit of EPA validation for its PFAS technology (AEC) is a strategic move to de-risk the technology and accelerate market adoption, a common approach in highly regulated environmental markets. The exploration of joint ventures for battery manufacturing aligns with capital-intensive industries where partnerships can mitigate financial burden and accelerate market entry.

Comparison to Industry Standards

• The company's stated "substantial doubt about our ability to continue as a going concern" is a critical red flag, indicating a financial position significantly below industry standards for sustainable operations.
• The reliance on a single customer (Pooph Inc.) for 69% of consolidated revenue is a high customer concentration risk, far exceeding typical healthy diversification benchmarks in most industries, making the company highly vulnerable to changes in that customer's performance or relationship.
• The significant cash burn from operating activities ($3.948 million used in H1 2025) without corresponding revenue growth or profitability is a concern, especially when compared to established cleantech companies that typically aim for positive operating cash flow or clear pathways to profitability.
• The lengthy sales cycles (months to years) for water treatment projects, as described, are standard for municipal and industrial infrastructure, similar to companies like Xylem Inc. or Evoqua Water Technologies, but BioLargo's current financial state makes these long cycles particularly challenging.
• The development of a liquid sodium battery (Cellinity) for long-duration energy storage positions BioLargo in a competitive market against established lithium-ion players (e.g., Tesla, LG Energy Solution) and emerging alternatives (e.g., Ambri, Form Energy). The claims of increased safety, sustainability, and longer life (10-20+ years) would, if fully validated and commercialized, surpass current lithium-ion benchmarks which typically have shorter lifespans and fire risks.
• The company's material weakness in internal controls is a significant governance issue, contrasting sharply with the robust control environments expected of publicly traded companies, especially those with diverse operations.

Management Changes

Corporate Governance

Related Party Transactions

• Conversion of $741,000 owed by Clyra Medical to BioLargo into 148,156 shares of Clyra common stock in June 2024.
• Clyra Medical's $575,000 guaranteed note offering is guaranteed by BioLargo Inc.
• BioLargo agreed to allow Vernal Bay Capital Group, LLC (who provided Clyra's line of credit) to convert Clyra shares into BioLargo common stock, which Vernal elected to do on January 9, 2023, converting 32,200 Clyra shares into 527,983 BioLargo common shares.
• BioLargo Energy Technologies, Inc. (BETI) investor may exchange BETI common stock into BioLargo common stock at a 20% discount to VWAP.
• Clyra Medical Series A Preferred Stock investors may exchange some or all of their Series A Preferred stock, plus accrued dividends, into shares of BioLargo common stock at a 20% discount of the volume weighted average price over the 30 prior trading days.

Stakeholder Impact

• Shareholders: Significant dilution risk from ongoing equity raises (Lincoln Park, Clyra offerings), increased net loss, and "going concern" warning could negatively impact share price and investment value.
• Employees: Potential for curtailment of operations if additional capital is not raised, which could impact employment. Stock option compensation is a significant part of executive and employee compensation.
• Customers: Delays in product delivery (e.g., Puppy Pads) and potential curtailment of operations could impact product availability and service quality.
• Suppliers/Creditors: Increased debt obligations, especially at Clyra Medical, and the "going concern" warning could raise concerns about timely payments and financial stability.
• Joint Venture Partners: Performance of subsidiaries and the parent company's financial health could impact joint venture prospects and existing agreements.

Next Steps

• Increase revenues and generate cash from operations.
• Generate cash from financing activities.
• Convert accounts receivable ($1,735,000) and note receivable ($3,572,000) into cash.
• Management may choose to curtail portions of operations if unable to raise additional cash.
• Complete the New Jersey PFAS project delivery and installation.
• Pursue EPA validation for AEC technology through a rigorous third-party pilot study.
• Continue marketing AROS system by Garratt-Callahan.
• Continue business development efforts for AOS in the European micropollutant market and domestic industrial/pharmaceutical wastewater.
• Continue manufacturing and testing prototype Cellinity battery cells.
• Complete the design on a larger sized Cellinity battery cell for industrial facilities.
• Develop manufacturing processes for Cellinity to allow scale production.
• Obtain technology validation for Cellinity from an independent organization.
• Explore multiple opportunities to commercialize Cellinity batteries through joint ventures with third parties.
• Recruit more qualified staff for BLEST to meet expanding demand for customers and internal projects.
• Source a new manufacturer for Puppy Pads products following the previous manufacturer's bankruptcy.
• Resolve issues not addressed in the First Amendment to Preferred Master Manufacturing Agreement related to the License Agreement and PMMA.

Key Dates

Recommendation

The filing presents a highly concerning financial picture, with a substantial 38% decline in revenue, a significantly widened net loss, and a large increase in cash used in operating activities. The explicit 'substantial doubt about our ability to continue as a going concern' statement is a critical red flag, indicating severe liquidity issues and an unsustainable operational model without continuous external financing. While the company is pursuing promising technologies like PFAS remediation and battery storage, their commercialization is slow and not yet generating sufficient revenue to offset losses. The high customer concentration and material weakness in internal controls further exacerbate the risk profile. Given the severe financial distress and the explicit going concern warning, a seasoned investor would likely recommend a strong sell to mitigate further capital loss.

Keywords

Cleantech, Water Treatment, PFAS Remediation, Odor Control, Battery Technology, Medical Devices, Environmental Engineering, SEC Filing, Quarterly Report, Going Concern, Revenue Decline, Net Loss, Cash Flow, Customer Concentration, Intellectual Property, Innovation, Sustainability